Geron stock jnj

18 Jun 2019 Earlier, the company had collaborated with Johnson and Johnson (JNJ Stock Report) but that collaboration has since ended. More importantly 

Geron's shares have been on a roller coaster ride throughout the year as investors bet on J&J's $JNJ next move. At one point a job posting linked to the drug  18 Jul 2018 In his comments during JNJ's quarterly earnings conference call, Mr. interest in Geron shares is 52.7 million shares according to Nasdaq's  More. Copy link to Tweet; Embed Tweet. #imetelstat Geron's imetelstat has so much potential ! $gernpic.twitter.com/CdjerLipfZ. 1 reply 2 retweets 12 likes. Reply. 18 Jun 2019 Earlier, the company had collaborated with Johnson and Johnson (JNJ Stock Report) but that collaboration has since ended. More importantly  27 Sep 2018 Patients currently enrolled in the ongoing imetelstat clinical trials will continue to be supported through the respective trial protocols, including  27 Sep 2018 Geron's imetelstat story already has had more twists than a Hitchcock film, and today that knocked Geron out of the billion-dollar biotech club as shares Geron's chief executive, John Scarlett, chalked up J&J's decision to a 

7 Feb 2018 Mid last year, the stock took a hit as investors became wary about the company's partnership with Johnson & Johnson (NYSE:JNJ) regarding its 

18 Jun 2019 Earlier, the company had collaborated with Johnson and Johnson (JNJ Stock Report) but that collaboration has since ended. More importantly  27 Sep 2018 Patients currently enrolled in the ongoing imetelstat clinical trials will continue to be supported through the respective trial protocols, including  27 Sep 2018 Geron's imetelstat story already has had more twists than a Hitchcock film, and today that knocked Geron out of the billion-dollar biotech club as shares Geron's chief executive, John Scarlett, chalked up J&J's decision to a  7 Feb 2018 Mid last year, the stock took a hit as investors became wary about the company's partnership with Johnson & Johnson (NYSE:JNJ) regarding its 

10 Apr 2017 Geron had hoped J&J would kick off the phase 3 in the middle of 2017, but has now pushed back its forecast to the fourth quarter. Shares in 

Geron is a clinical stage biopharmaceutical company focused on the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. 13 Mar 2020 Geron's (GERN) Q4 Earnings and Revenues Surpass Estimates. Zacks Equity Research March 13, 2020. JNJ REGN GERN VRTX. Geron's shares have been on a roller coaster ride throughout the year as investors bet on J&J's $JNJ next move. At one point a job posting linked to the drug 

Geron is a clinical stage biopharmaceutical company focused on the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies.

13 Mar 2020 Geron's (GERN) Q4 Earnings and Revenues Surpass Estimates. Zacks Equity Research March 13, 2020. JNJ REGN GERN VRTX. Geron's shares have been on a roller coaster ride throughout the year as investors bet on J&J's $JNJ next move. At one point a job posting linked to the drug 

27 Sep 2018 Patients currently enrolled in the ongoing imetelstat clinical trials will continue to be supported through the respective trial protocols, including 

29 Aug 2019 Geron Corporation GERN shares have risen 40% so far this year against the to imetelstat development by Johnson & Johnson JNJ last year. 3 May 2019 After Geron's (GERN) stock price experienced a meteoric rise and equally spectacular JNJ chose not to continue with Imetelstat, not Janssen. 27 Sep 2018 J&J's Janssen Biotech unit attributed the decision to a “strategic portfolio evaluation and prioritization of assets.” GP: Scientist in lab and  13 Mar 2020 Geron Corporation GERN incurred a loss of 15 cents per share in fourth-quarter 2019, Johnson & Johnson (JNJ): Free Stock Analysis Report Geron is a clinical stage biopharmaceutical company focused on the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. 13 Mar 2020 Geron's (GERN) Q4 Earnings and Revenues Surpass Estimates. Zacks Equity Research March 13, 2020. JNJ REGN GERN VRTX. Geron's shares have been on a roller coaster ride throughout the year as investors bet on J&J's $JNJ next move. At one point a job posting linked to the drug 

15 Jan 2019 J&J's decision proved particularly devastating for Geron because the biotech was clearly betting the house on this collaboration panning out. 29 Aug 2019 Geron Corporation GERN shares have risen 40% so far this year against the to imetelstat development by Johnson & Johnson JNJ last year. 3 May 2019 After Geron's (GERN) stock price experienced a meteoric rise and equally spectacular JNJ chose not to continue with Imetelstat, not Janssen. 27 Sep 2018 J&J's Janssen Biotech unit attributed the decision to a “strategic portfolio evaluation and prioritization of assets.” GP: Scientist in lab and  13 Mar 2020 Geron Corporation GERN incurred a loss of 15 cents per share in fourth-quarter 2019, Johnson & Johnson (JNJ): Free Stock Analysis Report Geron is a clinical stage biopharmaceutical company focused on the development of a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. 13 Mar 2020 Geron's (GERN) Q4 Earnings and Revenues Surpass Estimates. Zacks Equity Research March 13, 2020. JNJ REGN GERN VRTX.